Skip to main content

EGF Archives

Targeting diabetic kidney disease

Oct. 12, 2018—Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

Read more


Glowing receptors help find and track cancerous growth

May. 18, 2017—Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.

Read more


New target for colorectal cancer

Mar. 17, 2017—Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.

Read more


New fund honors spirit of Cohen’s innovative research

Aug. 25, 2016—When Tom Daniel, M.D., joined the Vanderbilt University faculty in December 1986, Stanley Cohen, Ph.D., had just been awarded the Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor (EGF).

Read more


Probing mutant EGF receptor regulation

Oct. 10, 2013—Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.

Read more


VU study identifies new mechanism for cancer development

Jun. 6, 2013—Researchers at Vanderbilt University Medical Center led by a 32-year-old postdoctoral fellow have discovered a new mechanism for the development of cancer that is challenging conventional scientific wisdom.

Read more


Plant compound stops colon cancer cells

Mar. 29, 2013—Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more